Search results for "Immunologic"

showing 10 items of 1115 documents

Identification of a Kd-restricted antigenic peptide encoded by murine cytomegalovirus early gene M84

2000

The two sister cytomegaloviruses (CMVs), human and murine CMV, have both evolved immune evasion functions that interfere with the major histocompatibility complex class I (MHC-I) pathway of antigen processing and presentation and are effectual in the early (E) phase of virus gene expression. However, studies on murine CMV have shown that E-phase immune evasion is leaky. An E-phase protein involved in immune evasion, namely m04-gp34, was found to simultaneously account for an antigenic peptide presented by the MHC-I molecule Dd. Recent work has demonstrated the induction of protective immunity specific for the E-phase protein M84-p65, one of two murine CMV homologues of the human CMV matrix …

MuromegalovirusPeptideBiologyMajor histocompatibility complexImmediate-Early ProteinsMiceOpen Reading FramesImmune systemVirologyAnimalsAmino Acid SequenceLymphocyte CountAntigens ViralGenes Immediate-EarlyGeneAntigenic peptidechemistry.chemical_classificationMice Inbred BALB CViral matrix proteinAntigen processingH-2 AntigensVirologyMolecular biologyPeptide FragmentschemistryCytomegalovirus earlybiology.proteinImmunologic MemoryT-Lymphocytes CytotoxicJournal of General Virology
researchProduct

Early gene m18, a novel player in the immune response to murine cytomegalovirus

2002

The identification of all antigenic peptides encoded by a pathogen, its T cell ‘immunome’, is a research aim for rational vaccine design. Screening of proteome-spanning peptide libraries or computational prediction is used to identify antigenic peptides recognized by CD8 T cells. Based on their high coding capacity, cytomegaloviruses (CMVs) could specify numerous antigenic peptides. Yet, current evidence indicates that the memory CD8 T cell response in a given haplotype is actually focused on a few viral proteins. CMVs actively interfere with antigen processing and presentation by the expression of immune evasion proteins. In the case of murine CMV (mCMV), these proteins are effectual in th…

MuromegalovirusT cellMolecular Sequence DataCD8-Positive T-LymphocytesBiologyVirus ReplicationVirusImmediate-Early ProteinsMiceImmune systemVirologymedicineAntigenic variationAnimalsCytotoxic T cellAntigens ViralGeneCells CulturedBase SequenceAntigen processingFibroblastsVirologymedicine.anatomical_structureViral replicationPeptidesImmunologic MemoryJournal of General Virology
researchProduct

Variation in RNA virus mutation rates across host cells.

2014

It is well established that RNA viruses exhibit higher rates of spontaneous mutation than DNA viruses and microorganisms. However, their mutation rates vary amply, from 10−6 to 10−4 substitutions per nucleotide per round of copying (s/n/r) and the causes of this variability remain poorly understood. In addition to differences in intrinsic fidelity or error correction capability, viral mutation rates may be dependent on host factors. Here, we assessed the effect of the cellular environment on the rate of spontaneous mutation of the vesicular stomatitis virus (VSV), which has a broad host range and cell tropism. Luria-Delbrück fluctuation tests and sequencing showed that VSV mutated similarly…

Mutation ratevirusesVirus Replicationmedicine.disease_causeMice[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCricetinaeBaby hamster kidney celllcsh:QH301-705.50303 health sciencesMutation[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases030302 biochemistry & molecular biology3. Good healthViral evolution[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyResearch Articlelcsh:Immunologic diseases. Allergy[SDE.MCG]Environmental Sciences/Global ChangesImmunologyBiologyMicrobiologyEvolution Molecular03 medical and health sciences[SDV.EE.ECO]Life Sciences [q-bio]/Ecology environment/EcosystemsCell Line TumorVirologyGeneticsmedicineAnimalsBiologyMolecular BiologyTropism030304 developmental biology[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthEvolutionary BiologyPoint mutationRNA virusVesiculovirusbiology.organism_classificationVirologyMolecular biology[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyViral replicationlcsh:Biology (General)MutationMicrobial EvolutionParasitology[SDE.BE]Environmental Sciences/Biodiversity and Ecologylcsh:RC581-607Population GeneticsPLoS Pathogens
researchProduct

Spatiotemporal mapping of the leprosy granuloma landscape

2022

Mycobacterium lepraeSettore MED/04 - Patologia GeneraleInfectious DiseasesGranulomaImmunological landscapeImmunologyImmunology and AllergyLymphocytes
researchProduct

Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance?

2009

Myeloid dendritic cells (DC) are "sentinels" of immunity, ideally positioned throughout the body gateways and equipped with unique properties to transport antigens from the periphery to lymphoid tissues. They are professional antigen-presenting cells transmitting incoming infectious signals to T cells, the key players of adaptive immunity. For induction of effective antigen-specific T-cell immunity, crosstalk of DC and naive T cells is mandatory. However, besides this essential immunostimulatory function of DC, consolidated findings from the DC research field in the last 10 years have shown that DC have an additional important function. They act as pivotal players in the peripheral toleranc…

MyeloidImmunologyCell CommunicationBiologyImmune toleranceMiceImmune systemAntigenImmunityT-Lymphocyte SubsetsmedicineImmune ToleranceImmunology and AllergyAnimalsHumansMyeloid CellsImmunologic SurveillancePeripheral toleranceGeneral MedicineDendritic CellsAcquired immune systemCrosstalk (biology)medicine.anatomical_structureImmunity ActiveImmunologyCytokinesHuman immunology
researchProduct

Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naïve T cells, and favors expansion of regulatory T ce…

2007

AbstractRetroviruses have developed immunmodulatory mechanisms to avoid being attacked by the immune system. The mechanisms of this retrovirus-associated immune suppression are far from clarified. Dendritic cells (DCs) have been attributed a decisive role in these pathogenic processes. We have used the Friend retrovirus (FV) mouse model in order to acquire further knowledge about the role of infection of DCs in virus-induced immunosuppression. About 20% of the myeloid DCs that were generated from the bone marrow of FV-infected mice carried FV proteins. The infection was productive, and infected DCs transmitted the virus in cell culture and in vivo. FV infection of DCs led to a defect in DC …

MyeloidImmunologyPopulationMedizinBone Marrow CellsMice Transgenicchemical and pharmacologic phenomenaCell CommunicationBiologyLymphocyte ActivationT-Lymphocytes RegulatoryBiochemistryMiceImmune systemAntigenImmune TolerancemedicineAnimalsCytotoxic T cellMyeloid CellseducationCell ProliferationAntigen PresentationMice Inbred BALB Ceducation.field_of_studyFollicular dendritic cellsModels ImmunologicalFOXP3hemic and immune systemsDendritic CellsCell BiologyHematologyFriend murine leukemia virusCell biologymedicine.anatomical_structureImmunologyBone marrowRetroviridae InfectionsBlood
researchProduct

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as pr…

2018

PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (7…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyNon-muscle invasive bladder cancer · Re-transurethral resection of the bladder · Recurrence · ProgressionSettore MED/24 - Urologia0302 clinical medicineRetrospective StudieRe-transurethral resection of the bladderRecurrenceImmunologicCause of DeathCumulative incidenceStage (cooking)Cause of deathProgressionIntravesicalAdministration IntravesicalLocal030220 oncology & carcinogenesisAdministrationBCG VaccineDisease ProgressionFemaleNon-muscle invasive bladder cancerHumanReoperationmedicine.medical_specialtyUrologyUrologyCystectomyArticleFollow-Up StudieCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansAdjuvantsAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesBladder cancerProportional hazards modelbusiness.industryNon-muscle invasive bladder cancer; Progression; Re-transurethral resection of the bladder; Recurrence; Adjuvants Immunologic; Administration Intravesical; Aged; BCG Vaccine; Cause of Death; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence Local; Neoplasm Staging; Proportional Hazards Models; Reoperation; Retrospective Studies; Urinary Bladder NeoplasmsRetrospective cohort studymedicine.diseaseNeoplasm RecurrenceUrinary Bladder NeoplasmsProportional Hazards ModelNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Mildronate and its neuroregulatory mechanisms: targeting the mitochondria, neuroinflammation, and protein expression.

2013

This review for the first time summarizes the data obtained in the neuropharmacological studies of mildronate, a drug previously known as a cardioprotective agent. In different animal models of neurotoxicity and neurodegenerative diseases, we demonstrated its neuroprotecting activity. By the use of immunohistochemical methods and Western blot analysis, as well as some selected behavioral tests, the new mechanisms of mildronate have been demonstrated: a regulatory effect on mitochondrial processes and on the expression of nerve cell proteins, which are involved in cell survival, functioning, and inflammation processes. Particular attention is paid to the capability of mildronate to stimulate…

Neurotoxicity SyndromeNerve Tissue ProteinsMitochondrionNeuroprotectionMiceAdjuvants ImmunologicNeuritismedicineAnimalsHumansLearningNeuroinflammationNeuronsbusiness.industryNeurogenesisNeurodegenerationNeurotoxicityParkinson DiseaseGeneral Medicinemedicine.diseaseMitochondriaNerve RegenerationRatsDisease Models AnimalNeuroprotective AgentsSynaptic plasticityNeurotoxicity SyndromesbusinessNeuroscienceMethylhydrazinesMedicina (Kaunas, Lithuania)
researchProduct

Preparation of hepatitis C virus structural and non-structural protein fragments and studies of their immunogenicity

2006

Abstract Plasmids pQE-60 and pQE-30 containing 6× His-tag sequence were used for expression of fragments of HCV structural and non-structural proteins in Escherichia coli (E. coli). The following fragments were used: core (1–98 aa), NS3 (202–482 aa), and tetramer of hypervariable region 1 (HVR1) of E2 protein. The constructed plasmids directed high levels of expression of HCV proteins in E. coli JM109. After purification by the metal-affinity chromatography on nickel–nitrilotriacetic acid (Ni–NTA) agarose, the His-tagged HCV proteins were used for immunization of BALB/c mice. All three proteins were able to induce high levels of specific antibodies and, in the case of the NS3 and HVR1 tetra…

Nitrilotriacetic AcidHepatitis C virusDose-Response Relationship ImmunologicViral Nonstructural ProteinsBiologymedicine.disease_causeSensitivity and SpecificityChromatography AffinityAntigen-Antibody ReactionsMiceViral Proteinschemistry.chemical_compoundPlasmidTetramerNickelmedicineAnimalsCloning MolecularEscherichia coliCell ProliferationMice Inbred BALB CNS3Viral Core ProteinsImmunogenicityvirus diseasesHepatitis C AntibodiesVirologyMolecular biologyPeptide FragmentsRecombinant Proteinsdigestive system diseasesHypervariable regionchemistryAgaroseFemaleImmunizationHepatitis C AntigensPeptidesSpleenBiotechnologyProtein Expression and Purification
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct